Selective inhibition of vascular smooth muscle cells to improve safety and efficacy of anti-restenotic therapy

Coronary artery disease (CAD) is a leading cause of death in the US and throughout the world. While balloon angioplasty and/or stent implantation is a common surgical treatment, the occurrence of restenosis in these patients leads to future complications and additional surgical intervention. To this end, therapies that utilize drug-eluting stents (DES) non-selectively reduce vascular smooth muscle cell (VSMC) growth, minimizing restenosis, but also inhibit growth of vascular endothelial cells (VEC), leading to post-operative thrombosis and death. This technology describes a microRNA-based (miRNA-based) approach to prevent restenosis by inhibiting proliferative VSMCs, while selectively promoting reendothelialization and persevering VEC function. As such, this technology retains the patency maintenance required of CAD treatments while lowering the risk of post-operative thromboses, ultimately improving long-term patient outcomes.

Reduce restenosis associated with surgical interventions for coronary artery diseaseLowers the risk of post-operative thrombosis associated with drug eluting stentsCan achieve restenosis reduction and minimize post-operative complications in a single comprehensive treatment Simple process to incorporate the miRNA into the p27 vector Patent Information:Patent Pending (WO/2013/152230)Tech Ventures Reference: IR CU12261

Inhibition of VSMC proliferation in other contexts, such as atherosclerosis, arterial injury and vascular access failure in hemodialysis patientsDepletion of mixed cultures of VSMC in laboratory experimentation A model of defective growth in VSMCSelective inhibition of growth of any number of cell types

None

USA